SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as traders debate its potential for a parabolic rally, with many in the community closely monitoring technical indicators and chart patterns for a breakout. Investors are actively discussing the coin's future as a major crypto asset, balancing high hopes for institutional adoption against frustration over its recent price stagnation.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative interest as traders discuss its potential role in Japan's expanding IoT and tokenized data ecosystem. The community remains deeply divided, with long-term holders pointing to long-term accumulation and partnership rumors, while skeptics emphasize the lack of recent price momentum and competitive shifts within the project's leadership.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is active and buzzing with speculative momentum as traders rotate between $MULN and associated tokens, fueled by community-led 'pump' narratives. Despite persistent warnings from some users about the project's controversial history, participants are rallying around high-risk, low-market-cap trading strategies in hopes of repeating past volatility.

Ascend is a prediction perpetuals platform that allows you to trade prediction markets with up to 100x leverage. Ascend is multi-chain, ZK-settled on Midnight, secured by Cardano. Ascend turns prediction markets into real-time, tradable markets. Instead of simply betting on outcomes and waiting for resolution, users can trade the probability of events (like BTC hitting $100K) using a perpetual-style engine, entering and exiting positions anytime. Trades are executed off-chain for speed and then batch-settled on Midnight using zero-knowledge (ZK) proofs, giving users a seamless experience with strong on-chain guarantees. This creates a more dynamic, liquid, and capital-efficient way to trade information and belief.

Project Ascend

Project Ascend is capturing significant investor attention as the community anticipates a major rally following the upcoming main-net launch and current consolidation phase. Market participants are actively buzzing about the project's growth potential, framing the current price action as a key accumulation opportunity.

ARK ETF Trust - ARK Space & Defense Innovation ETF

ARK Space Exploration & Innovation ETF

The ARK Space Exploration & Innovation ETF is garnering significant attention as investors speculate on its potential to capitalize on the growing space economy, particularly with ongoing excitement surrounding a possible SpaceX IPO. Community members are actively debating the fund's current holdings and comparing it to other space-focused investment vehicles while watching for future portfolio shifts.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain is currently drawing significant community attention as investors debate its long-term utility versus recent price underperformance, with many actively discussing the impact of upcoming network upgrades like Hayabusa and the EU's Digital Product Passport. While some holders remain hopeful that these institutional adoption catalysts will fuel a recovery, others express frustration over stagnant growth and the foundation's treasury management, fueling intense debates on social platforms about whether the asset is finally poised for a turnaround or entering a cycle of decline.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is gaining significant community attention as investors highlight its deflationary burn mechanisms and expanding decentralized AI ecosystem, with many participants actively discussing potential price momentum fueled by privacy-focused AI narratives. The conversation is currently dominated by 'true long' bulls who view the token as a long-term play on artificial intelligence, frequently comparing its current market cap to other sector leaders while anticipating further ecosystem developments.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad ($GIGA) is trending as the community rallies around its unique expansion into physical retail supplements and its persistent presence in internet culture. Supporters are actively highlighting its role as a long-term 'asymmetric' play, often drawing comparisons to other major meme assets while emphasizing the importance of community conviction through market volatility.

MarketWise, Inc. develops and operates a multi-brand digital subscription services platform. It is a subscription services platform that provides independent financial research, analytical tools, and software primarily to retail investors across digital channels. The company was founded in 1999 and is headquartered in Baltimore, MD.

Marketwise Inc - Ordinary Shares - Class A

MarketWise is attracting community interest as investors weigh its recent billing growth and profitability against a complex capital structure and historical share price volatility. Discussions are centered on the stock's status as a deep-value play, with many participants monitoring insider accumulation and potential acquisition interest in the digital subscription platform.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently drawing significant attention from investors as it aggressively scales its 'physical AI' infrastructure and secures major partnerships, most notably with Volkswagen, to integrate its autonomous driving software. The community remains deeply divided, with bulls pointing to these high-tech milestones and global expansion plans as evidence of long-term value, while bears focus on delivery volatility and ongoing downward price pressure from institutional trading patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates

The Joint (JYNT) delivered earnings and revenue surprises of +166.67% and +5.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix Inc (NASDAQ:CRMD) Receives Consensus Rating of "Moderate Buy" from Analysts

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has been given a consensus rating of 'Moderate Buy' by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One...

210,831 Shares in CorMedix Inc $CRMD Acquired by Del Sette Capital Management LLC

Del Sette Capital Management LLC acquired a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund...

CorMedix (CRMD) Expected to Announce Earnings on Wednesday

CorMedix (NASDAQ:CRMD) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

CorMedix (NASDAQ:CRMD) Earns Market Outperform Rating from Citizens Jmp

Citizens Jmp restated a "market outperform" rating and set a $19.00 price target on shares of CorMedix in a research note on Tuesday...

CorMedix (NASDAQ:CRMD) Price Target Raised to $14.00

Leerink Partners boosted their price objective on shares of CorMedix from $13.00 to $14.00 and gave the stock an "outperform" rating in a research note on Tuesday...

CorMedix (NASDAQ:CRMD) Price Target Raised to $15.00

Needham & Company LLC raised their price target on shares of CorMedix from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday...

<ul class="summary-bullets"><li>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections.</li><li>Rezzayo is already approved in the U.S. for the treatment of candidemia and invasive candidiasis in adults.</li><li>The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.</li></ul>Shares of CorMedix Therapeutics (CRMD) rose 2% on Monday after the company announced positive results from its late-stage trial evaluating its antifungal drug Rezzayo to prevent invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Allogeneic hematopoietic stem cell transplantation is a curative procedure for high-risk blood cancers and marrow diseases, where healthy blood-forming cells from a donor replace a patient's diseased marrow. Patients undergoing the procedure face prolonged periods where their immunity is not strong enough to ward off infections from fungi, including candida, aspergillus, and pneumocystis.Rezzayo is already approved in the U.S. for the treatment of fungal infections, candidemia, and invasive candidiasis in adults. The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.<h2 class="st-heading-2">Trial Takeaways</h2>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections, the company said. Fungal-free survival at day 90 was 60.7% in the Rezzayo group versus 59.0% in the group that received a standard antimicrobial regimen, it added.Furthermore, the drug was well tolerated with a safety profile showing a favorable benefit/risk profile in the patient population, the company said, while adding that the drug also demonstrated fewer interactions with other drugs and discontinuations due to toxicity.CorMedix now expects to have a meeting with the U.S. Food and Drug Administration in the coming months before submitting an application for the drug for the indication. The company expects to file the application in the second half of 2026 based on the trial results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CRMD jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels. According to internal data, retail chatter around the stock jumped 1400% over the past day.A Stocktwits user expressed optimism for the stock rising into earnings while adding that “today was great news.”<stembedurl>https://www.stocktwits.com/S2730/message/651521499</stembedurl>Another user expressed muted enthusiasm, opining that the results, though good, are not “transformative.”<stembedurl>https://www.stocktwits.com/ReturnOfEsquire/message/651515352</stembedurl> <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> has fallen 17% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sndk-stock-surges-nearly-8-to-hit-fresh-record-high-what-s-behind-the-investor-optimism-april-27/cZBND2dReP8">SNDK Stock Surges Nearly 8% To Hit Fresh Record High – What’s Behind The Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market 

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 

Equity

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 


CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix says Phase 3 ReSPECT data show rezafungin is non-inferior in fungal prevention, supporting FDA filing plans and a $2 billion market outlook.read more...

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRMD News

CRMDCorMedix Inc